医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor

2023年02月01日 PM03:30
このエントリーをはてなブックマークに追加


 

TOKYO

Shin-Nihon Public Affairs Co. (Head Office: Tokyo; President: Yasushi Kohara) today announced Mr. Yasuhisa Shiozaki as special advisor. Mr. Shiozaki is a former Chief Cabinet Secretary, and Minister of Health, Labour and Welfare, and is well versed in an extremely wide range of policy areas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230130005801/en/

Yasuhisa Shiozaki (Photo: Business Wire)

Yasuhisa Shiozaki (Photo: Business Wire)

“I will utilize my knowledge and experience I have accumulated over many years in the fields of politics and public administration to develop a variety of policy advocacy activities aimed at solving global issues,” said Shiozaki upon the appointment.

When he served as Minister of Health, Labour, and Welfare, he led to launch the Action Plan for Whole Genome Analysis, etc. to promote genomic medicine for cancer and intractable diseases, and strongly promoted data health reform. He also worked on many other policy issues, including the issue of drug resistance (AMR). After becoming a private citizen, he established the Study Group for the Promotion of Genomic Medicine in February 2022, which he continues to preside over and disseminate policy proposals for the realization of “patient-driven, patient-rewarded” genomic medicine.

“Mr. Shiozaki’s extensive experience in government and public administration will serve us well as we continue to provide a higher level of policy advocacy services, especially in the medical field to support the fostering of the genome industry as well as the raising of the overall healthcare industry toward the goal of becoming a “Health Advanced Nation”,” said Kohara.

Read Shiozaki’s full biography at https://www.y-shiozaki.or.jp/en/profile/index.html
Learn more at https://www.snpa.co.jp/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005801/en/

CONTACT

Yasushi Kohara

+81-50-6882-8582

contact_us@snpa.co.jp

同じカテゴリーの記事 

  • Neu-REFIX Beta葡聚糖获得美国FDA罕见儿科疾病和孤儿药认定,可用于治疗杜氏肌营养不良症
  • AIHA To Advance Global OEHS Through International Strategic Partnership, Vietnam Delegation
  • GC Aesthetics®推出YOUTHLY™:中国乳房植体进入新时代
  • Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy
  • Neuraptive Therapeutics宣布在2024年美国手外科学会(ASSH)年会上公布NTX-001的2期顶线中期结果